CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members

By E. Trompouki, E. Hatzivassiliou, Theodore Tsichritzis, H. Farmer, Alan Ashworth, G. Mosialos. Nature, 2003

963 citations recorded by the source corpus.

Subfields: Cancer Research, Dermatology, Immunology

View Paper: https://www.semanticscholar.org/paper/b18e20d8901c4da42111fa3bab33629000861c9f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Immunology

Citations in the corpus

The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. (2005, background): “…DUB substrates shRNA vectors efficiently suppressed GFP-USP1 ex-have been identified (Brummelkamp et al., 2003; Cumpression (Figure 2C).mings et al., 2004; Graner et al., 2004; Kovalenko et al., To study endogenous USP1 protein, a polyclonal anti-2003; Li et al., 2002; Trompouki et al., 2003).”
Bcl10 activates the NF-κB pathway through ubiquitination of NEMO (2004, background): “Recent studies show that the tumour suppressor gene product CYLD negatively regulates NF-κB activation by acting as a deubiquitinating enzym”
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. (2007, background): “…is a deubiquitinating enzyme that removes ubiquitin moieties from activated TRAF2, TRAF6, IKKg, and BCL3, thereby interfering with NF-kB signaling at multiple regulatory levels (Brummelkamp et al., 2003; Kovalenko et al., 2003; Massoumi et al., 2006; Regamey et al., 2003; Trompouki et al., 2003).”
Ubiquitin signalling in the NF-κB pathway (2005, background): “One of these DUBs is the cylindromatosis tumour suppressor protein CYLD, which inhibits IKK activation by cleaving Lys 63-linked polyubiquitin chains on several proteins, including TRAF2, TRAF6 and NEM”
Temporal analysis of phosphotyrosine-dependent signaling networks by quantitative proteomics (2004, background): “The tumor suppressor CYLD has recently been shown to be a critical regulator of NF kappa B–dependent apoptosis, and our data now link this protein to EGFR signalin”
Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB (2003, methodology): “This was immunoprecipated with either non-immune serum (n.i.) or Flag antibody from both untreated cells (basal) or cells treated for 20 min. with TNF-a(20 0 ) and lysates were incubated with GST-IkBa (1-72) in the presence of 32P-gATP (upper panel).”
The NF-κB pathway (2005, background): “Interestingly the tumour suppressor CYLD is a deubiquitinylating enzyme that inhibits ubiquitinylation of TRAF proteins and activation of NF-B (Brummelkamp et al., 2003; Kovalenko et al., 2003; Trompouki et al., 2003 ).”